- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PN1301 | Recombinant Protein-Porcine enterovirus 9 Protein VP0 (a.a.2 to 315) | O41174 | 100 µg | 1195 | |
PN1302 | Recombinant Protein-Porcine enterovirus 9 Protein VP1 (a.a.554 to 835) | O41174 | 100 µg | 1195 | |
PN1303 | Recombinant Protein-Porcine enterovirus 9 Protein VP2 (a.a.70 to 315) | O41174 | 100 µg | 1195 | |
PN1304 | Recombinant Protein-Porcine enterovirus 9 Protein VP3 (a.a.316 to 553) | O41174 | 100 µg | 1195 | |
RPN1301 | cDNA-Porcine enterovirus 9 Protein VP0 (a.a.2 to 315) | O41174 | 2 µg | 1565 | |
RPN1302 | cDNA-Porcine enterovirus 9 Protein VP1 (a.a.554 to 835) | O41174 | 2 µg | 1405 | |
RPN1303 | cDNA-Porcine enterovirus 9 Protein VP2 (a.a.70 to 315) | O41174 | 2 µg | 1225 | |
RPN1304 | cDNA-Porcine enterovirus 9 Protein VP3 (a.a.316 to 553) | O41174 | 2 µg | 1185 |
Porcine enterovirus cDNA and recombinant antigen
Porcine enterovirus (PEV) is a group of viruses that belong to the Picornaviridae family and infect pigs. The most common PEV strains are porcine enterovirus A (PEVA) and porcine enterovirus B (PEVB), which can cause a variety of symptoms, ranging from mild to severe. PEV can cause a range of diseases, including meningitis, encephalomyelitis, polio-like syndromes, and respiratory diseases. The virus is spread through direct contact between pigs or through contaminated feed and water. PEV is considered a significant economic burden for the pig industry, as it can lead to reduced growth, increased death rates, and decreased production efficiency. There is currently no specific treatment for PEV, but vaccines are available to help reduce the incidence and severity of the disease.
The porcine enterovirus (PEV) antigen refers to a substance that is specifically recognized and targeted by the immune system as being foreign or harmful. Antigens are typically proteins or other molecules found on the surface of viruses and bacteria, and they trigger an immune response. In the case of PEV, the virus surface antigen can be used to develop diagnostic tests for the virus and to potentially design vaccines. By exposing the immune system to a specific antigen, it can learn to recognize and respond to the virus if it encounters it again in the future. In other words, the PEV antigen can be used to help the body build immunity against the virus.
The porcine enterovirus (PEV) genome is the genetic material of the virus that contains all the information necessary for its replication and survival. PEV has a small, single-stranded RNA genome that is approximately 7.5 kilobases in length. The genome encodes a variety of viral proteins, including the structural proteins that form the virus shell, the enzymes required for replication, and the proteins involved in immune evasion. Studying the PEV genome is important for understanding the virus’s biology, pathogenesis, and evolution. This information can be used to develop better diagnostic tests, vaccines, and treatments for PEV infections. Additionally, the genetic variation of PEV strains can inform the development of molecular epidemiology studies and help track the spread of the virus in the pig population.
Porcine enterovirus 9 (PEV9) is a common cause of disease in pigs. The virus contains four main proteins: Protein VP0, Protein VP1, Protein VP2, and Protein VP3.
Protein VP0 is a precursor protein that is cleaved into VP2 and VP4 during virus assembly.
Protein VP1, VP2, and VP3 are structural proteins that are involved in the formation of the viral capsid. These proteins are critical for the stability of the virus and for protecting the viral genome during transmission.
Understanding the role of these proteins in the replication and assembly of PEV9 is essential for developing effective treatments and vaccines. Ongoing research in this area aims to identify new targets for intervention and to develop new strategies for combatting this common pig pathogen.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple